233 related articles for article (PubMed ID: 20212225)
1. Bevacizumab for malignant gliomas.
Iwamoto FM; Fine HA
Arch Neurol; 2010 Mar; 67(3):285-8. PubMed ID: 20212225
[TBL] [Abstract][Full Text] [Related]
2. Anti-angiogenic approaches to malignant gliomas.
Soffietti R; Trevisan E; Bertero L; Bosa C; Ruda R
Curr Cancer Drug Targets; 2012 Mar; 12(3):279-88. PubMed ID: 22229250
[TBL] [Abstract][Full Text] [Related]
3. Treatment of recurrent high-grade gliomas.
Wen PY; Brandes AA
Curr Opin Neurol; 2009 Dec; 22(6):657-64. PubMed ID: 19770658
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
Cuneo KC; Vredenburgh JJ; Sampson JH; Reardon DA; Desjardins A; Peters KB; Friedman HS; Willett CG; Kirkpatrick JP
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2018-24. PubMed ID: 21489708
[TBL] [Abstract][Full Text] [Related]
5. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas.
Chamberlain MC
Cancer; 2010 Sep; 116(17):3988-99. PubMed ID: 20564141
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
7. Recurrent malignant gliomas.
Kirkpatrick JP; Sampson JH
Semin Radiat Oncol; 2014 Oct; 24(4):289-98. PubMed ID: 25219814
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of the glioma microenvironment].
Herrlinger U; Platten M
Nervenarzt; 2015 Jun; 86(6):684, 686-8, 690-1. PubMed ID: 25962344
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic therapy of brain tumors: the role of bevacizumab.
Trevisan E; Bertero L; Bosa C; Magistrello M; Pellerino A; Rudà R; Soffietti R
Neurol Sci; 2014 Apr; 35(4):507-14. PubMed ID: 24442487
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
11. [Bevacizumab associated with radiotherapy and temozolomide as a first line treatment for high-grade gliomas: one answer but too many questions].
Lebrun-Frenay C
Rev Neurol (Paris); 2014 Apr; 170(4):235-6. PubMed ID: 24776742
[No Abstract] [Full Text] [Related]
12. Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.
Everson RG; Graner MW; Gromeier M; Vredenburgh JJ; Desjardins A; Reardon DA; Friedman HS; Friedman AH; Bigner DD; Sampson JH
Expert Rev Anticancer Ther; 2008 May; 8(5):717-32. PubMed ID: 18471045
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S; Rich JN
Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.
Narayana A; Kelly P; Golfinos J; Parker E; Johnson G; Knopp E; Zagzag D; Fischer I; Raza S; Medabalmi P; Eagan P; Gruber ML
J Neurosurg; 2009 Jan; 110(1):173-80. PubMed ID: 18834263
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas.
de Groot JF; Yung WK
Cancer J; 2008; 14(5):279-85. PubMed ID: 18836331
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic therapy with bevacizumab in recurrent malignant gliomas: analysis of the response and core pathway aberrations.
Zhang W; Qiu XG; Chen BS; Li SW; Cui Y; Ren H; Jiang T
Chin Med J (Engl); 2009 Jun; 122(11):1250-4. PubMed ID: 19567132
[TBL] [Abstract][Full Text] [Related]
17. Irradiation and bevacizumab in high-grade glioma retreatment settings.
Niyazi M; Ganswindt U; Schwarz SB; Kreth FW; Tonn JC; Geisler J; la Fougère C; Ertl L; Linn J; Siefert A; Belka C
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):67-76. PubMed ID: 21030162
[TBL] [Abstract][Full Text] [Related]
18. The paradoxical effect of bevacizumab in the therapy of malignant gliomas.
Thompson EM; Frenkel EP; Neuwelt EA
Neurology; 2011 Jan; 76(1):87-93. PubMed ID: 21205697
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor inhibitors in malignant gliomas.
Brastianos PK; Batchelor TT
Target Oncol; 2010 Sep; 5(3):167-74. PubMed ID: 20821351
[TBL] [Abstract][Full Text] [Related]
20. [Advances of VEGF related molecular promoting tumor angiogenesis and targeting therapy].
Guo ZY; Cao BL
Zhonghua Bing Li Xue Za Zhi; 2010 Apr; 39(4):282-4. PubMed ID: 20654135
[No Abstract] [Full Text] [Related]
[Next] [New Search]
